A randomised comparison of low or high dose IFN-alpha in newly diagnosed CML patients shows no difference in major cytogenetic response rate or survival between the two groups - Results of MRC CML V and HOVON 20 trials. (BLOOD, 2001)

(untitled) - Shepherd, P; Kluin-Nelemans, H; Richards, S; Le Cessie, S; Party, M; Grp, H